Baird on Alto Neuroscience (ANRO): 'Incrementally positive on Phase 2 CIAS initiation'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Alto Neuroscience Initiates Phase 2 Study of ALTO-101, a Novel PDE4 Inhibitor, in Cognitive Impairment Associated with Schizophrenia
June 20, 2024 8:05 AM EDTALTO-101 has been shown to positively impact cognition and key cognition-related EEG markers in humans when delivered orally
Novel transdermal formulation of ALTO-101 exhibited favorable pharmacokinetics and tolerability, greater drug exposure, and fewer PDE4 associated adverse events compared to ALTO-101 administered orally
LOS ALTOS, Calif.--(BUSINESS WIRE)-- Alto Neuroscience, Inc. (Alto)... More
Amit Etkin, M.D., Ph.D., Founder and CEO of Alto Neuroscience, Named an EY Entrepreneur Of The Year® 2024 Bay Area Award Winner
June 18, 2024 8:05 AM EDTDr. Etkin recognized as a Bay Area winner out of 26 finalists by an independent panel of judges
Entrepreneur Of The Year celebrates ambitious entrepreneurs who are shaping the future across all industries
LOS ALTOS, Calif.--(BUSINESS WIRE)-- Alto Neuroscience, Inc. (Alto) (NYSE:... More
